Last reviewed · How we verify
Complement 3 Glomerulopathy
Approved treatments
- Fabhalta · Novartis
Iptacopan binds to Factor B, regulating C3 cleavage and downstream effects in the alternative complement pathway, controlling IVH and EVH in PNH and inhibiting local activation in IgAN and C3G.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Complement 3 Glomerulopathy patent landscape — cliff calendar, originator estates, attackable patents
- Complement 3 Glomerulopathy treatment landscape brief
- Complement 3 Glomerulopathy treatment updates RSS
Frequently asked questions about Complement 3 Glomerulopathy
What drugs treat Complement 3 Glomerulopathy?
Tracked treatments include Fabhalta.
What is the treatment for Complement 3 Glomerulopathy?
Standard treatment for Complement 3 Glomerulopathy includes Fabhalta. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Complement 3 Glomerulopathy patent cliff · Complement 3 Glomerulopathy CI report
- Treatment: Fabhalta · Novartis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing